Author  
Place of duty  
Title   C3H ¸¶¿ì½º ¼¶À¯À°Á¾ ¿Â¿­Ä¡·á½Ã Hydralazine ÀÌ ¹ÌÄ¡´Â ¿µÇâ ( The Effect of Hydralazine on Hyperthermic Treatment of C3H Mouse Fibrosarcoma )
Publicationinfo   1995 Jan; 027(04): 671-680.
Key_word   C3H mouse fibrosarcoma, Hydralazine, Hyperthermia, Hypoxic fraction
Full-Text  
Abstract   Hypoxic cells comprise l0~20% of tumor cells and are more sensitive to hyperthermia. By decreasing tumor blood flow artificially and thus increasing the hypoxic fraction in the tumor, the cytotoxic effect of hyperthermia can be increased. Hydralazine is an antihypertensive drug and its main mechanism is relaxation of the vascular smooth muscle of arterioles rather than veins. Administration of hydralazine causes a decrease in vascular resistance and an increase in blood flow in normal tissue, but since the vasculature of tumor is not responsive to such a drug, blood flow in tumors is decreased because of steal phenomenon. Thus the hypoxic fraction in the tumor is increased, and the tumor becomes more sensitive to hyperthermia. Therefore, to evaluate the hydralazine effect on hyperthermia, the tumor growth delay was investigated and the change in the hynoxic fraction of the tumor was estimated using C3H mouse fibrosarcoma(FSaII) with hypoxic fractions af usual range. In 6 mm FSaII tumors grow- ing in the dorsum of the foot, administration af 5 or l0 mg/kg of hydralazine was followed by 43`C, hyperthermia for 60 minutes. Tumor growth times (TGT) to reach a tumor volume of 500 mm(2) were 7.11+-0.84 days and 7.44+- 1.13 days for controls and 10 mg/kg of hydralazine only. TGTs for hyperthermia alone and administration of 5 or 10 mg/kg of hydralazine followed by hyperthermia were 10.34+-2.17 days, 13.38+-1.82 days and 14.47+- 0.67 days, respectively. Elongation of tumor growth delay by administration of 5 or l0 mg/kg of hydralazine in addition to hyperthermia were statistically significant (0.025
Àú ÀÚ   ¹Ú¿ìÀ±(Woo Yoon Park),ÇϼºÈ¯(Sung Whan Ha),¹ÚÂùÀÏ(Charn Il Park)